

Indices	Close	Previous	Chg. %
SENSEX	55,381	55,566	-0.33%
NIFTY	16,523	16,585	-0.37%
NIFTY BANK	35,621	35,487	0.38%
NIFTY AUTO	11,563	11,587	-0.20%
NIFTY IT	29,261	29,679	-1.41%

Indices	Close	Previous	Chg. %
DJIA	32,813	32,990	-0.54%
NASDAQ	11,994	12,081	-0.72%
S&P 500	4,101	4,132	-0.75%
DAX	14,340	14,388	-0.33%
CAC 40	6,419	6,469	-0.77%
FTSE 100	7,533	7,608	-0.98%
HANG SENG	21,295	21,415	-0.56%
SSE INDEX	3,182	3,186	-0.13%
NIKKEI 225	27,458	27,280	0.65%

Nifty Gainers	Chg. %	Nifty Losers	Chg. %
JSWSTEEL	3.56	KOTAKBANK	-3.65
COALINDIA	2.02	SUNPHARMA	-3.25

Type	2 <sup>nd</sup> June, 2022	1 <sup>st</sup> June, 2022
Gold	1,846.30	1,835.00
Brent Crude	117.26	119.4

Type	Current	Previous	Change (bps)
G- Sec -6.54% GOI	7.41	7.40	.1
T-Bill 91 days	4.88	4.88	0
10 Year US Treasury	2.931	2.061	1

Rate	
Repo Rate	4.40
Cash Reserve Ratio	4.50
RBI Bank Rate	4.65
Statutory Liquidity Ratio	18.00
CPI	7.79

### Markets End a Volatile Session Lower

- Indian shares fluctuated before ending slightly lower on Wednesday, with inflation and growth worries weighing on markets.
- Geopolitical tensions also intensified after U.S. President Joe Biden pledged to send Ukraine more advanced rocket systems and munitions to more precisely strike key targets on the battlefield.
- The dollar strengthened in international markets and U.S. treasury yields rose, as hawkish comments from Fed Governor Christopher Waller earlier this week caused investors to trim expectations for a pause in the rate hike cycle after two 50 basis point hikes each this month and next.
- Sun Pharmaceutical's share price fell on Tuesday after India's biggest pharmaceutical company logged a consolidated net loss. Sun Pharma recorded a March quarter consolidated net loss after tax 22.77 billion rupees versus profit of 8.94 billion rupees year ago.

### Global & Asian market overview

- **European stocks** closed notably lower as disappointing economic data from the region, and rising concerns over inflation and interest rates rendered the mood bearish. A sell-off in the U.S. market further hurt sentiment.
- **US stocks** fluctuated over the course of the trading session before ending the day mostly lower. The lower close on Wall Street may partly have reflected a negative reaction to comments from JPMorgan Chase (JPM) CEO Jamie Dimon, who urged investors to brace for an economic hurricane.
- **Asian stocks** ended mixed after a private survey showed Chinese factory activity shrank less sharply than expected in May.

### Debt Market Overview

- **US Treasuries**
  - Treasuries showed a notable move to the downside during trading on Wednesday, extending the pullback seen in the previous session. Bond prices came under pressure in morning trading and remained firmly negative throughout the afternoon. As a result, the yield on the benchmark ten-year note, which moves opposite of its price, advanced 8.7 basis points to 2.931 percent
- **Corporate Bond Sales**
  - The sale of corporate bonds in the first two months of this fiscal year is less than half of the number in the corresponding period last year, as companies are holding back their borrowing plans amid volatile interest rate movements. Borrowers are waiting for a possible toning down of commentary by the central bank governor in the monetary policy next week, after promising not to "shock" the market with sharp rate changes.

**Cholamandalam Securities Limited**

**Member: BSE, NSE, MSE**

**Regd. Office: Dare House, 2 (Old) # 234 N.S.C Bose Road, Chennai – 600 001.**

**Website: www.cholawealthdirect.com**

**Email id – customercarewm@chola.murugappa.com**

**CIN U65993TN1994PLC028674**

Chola Securities Limited (CSL), AMFI registered mutual fund distributor, is a leading southern India based Stock broker. Our focus area of coverage within the Indian market is Mid and Small caps with a focus on companies from southern India.

Our Institutional Equities services are carried out in partnership with RCCR, a boutique Investment research and Corporate Advisory firm founded by a team with extensive experience in the Asset management industry.

RESEARCH			
Kedar S Kadam	DGM & Head of Research	+91-44 - 4004 7361	kedarsk@chola.murugappa.com
Mugilan K	Technical Analyst	+91-44 - 4004 7353	mugilank@chola.murugappa.com
Nilesh Patil	Fundamental Analyst	+91-44 - 4004 7266	nileshmp@chola.murugappa.com
Balaji H	Compliance Officer	044-30007226	balajih@chola.murugappa.com
Lakshmi Sundaram	Customer service	1800 425 4477	lakshmis@chola.murugappa.com

**DISCLAIMER:**

This report is for private circulation and for the personal information of the authorized recipient only, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not provide individually tailor-made investment advice and has been prepared without regard to any specific investment objectives, financial situation, or any particular needs of any of the persons who receive it.

The research analyst(s), Cholamandalam Securities Limited (CSL), AMFI registered mutual fund distributor, who is primarily responsible for this report certifies that: (1) all of the views expressed in this report accurately reflect his or her personal opinions about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of Cholamandalam Securities Limited makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete.

The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein Cholamandalam Securities Limited reserves the right to make modifications and alterations to this statements as may be required from time to time without any prior approval. Cholamandalam Securities Limited, its affiliates, directors and employees may from time to time, effect or have effect an own account transaction in or deal as agent in or for the securities mentioned in this report. The recipient should take this into account before interpreting the report.

All investors may not find the securities discussed in this report to be suitable. Cholamandalam Securities Limited recommends that investors independently evaluate particular investments and strategies. Investors should seek the advice of a financial advisor with regard to the appropriateness of investing in any securities / investment strategies recommended in this report. The appropriateness of a particular investment or strategy will depend on an investor's individual preference. Past performance is not necessary a guide to future performance. Estimates of future prospects are based on assumptions that may not be realized. Re-publication or redistribution in any form, in whole or in part, is prohibited.

No part of this material may be duplicated in any form and/or redistributed without Cholamandalam Securities Limited prior written consent.

The news items appearing in this are collected from various media sources and we make no representations that it is complete or accurate

## **Cholamandalam Securities Limited**

*(A subsidiary of Cholamandalam Investment and Finance Company Ltd.)*

Dare House, 2, N.S.C. Bose Road, Parrys, Chennai 600001, India

Tel: 91.44.30007172 / 91.44.30007370 Fax: 91.44.30007373

Website: www.cholawealthdirect.com

CIN – U65993TN1994PLC028674